Since Jelinek et al10 reported the absence of JAK2V617F mutation in patients with Ph+CML; it was thought that JAK2 V617F mutation and BCR-ABL translocation were mutually exclusive. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.